Clinical Trial Update: Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study [Phase 4]

View source ↗

Summary

This ClinicalTrials.gov entry describes a Phase 4, single-arm exploratory study evaluating iparomlimab and tuvonralimab in combination with bevacizumab after pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Hebei Medical University Fourth Hospital | Conditions: PD-(L)1, CTLA-4 | Phase 4 | Status: NOT_YET_RECRUITING